Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Net Income (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Net Income data on record, last reported at -$118.2 million in Q4 2025.

  • For Q4 2025, Net Income fell 49.74% year-over-year to -$118.2 million; the TTM value through Dec 2025 reached -$340.9 million, down 26.67%, while the annual FY2025 figure was -$340.9 million, 26.45% down from the prior year.
  • Net Income reached -$118.2 million in Q4 2025 per VRDN's latest filing, down from -$35.1 million in the prior quarter.
  • Across five years, Net Income topped out at -$14.1 million in Q3 2021 and bottomed at -$118.2 million in Q4 2025.
  • Average Net Income over 5 years is -$52.9 million, with a median of -$48.1 million recorded in 2023.
  • The widest YoY moves for Net Income: up 68.11% in 2021, down 177.74% in 2021.
  • A 5-year view of Net Income shows it stood at -$28.9 million in 2021, then tumbled by 58.17% to -$45.8 million in 2022, then tumbled by 45.61% to -$66.7 million in 2023, then fell by 18.44% to -$79.0 million in 2024, then plummeted by 49.74% to -$118.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$118.2 million in Q4 2025, -$35.1 million in Q3 2025, and -$100.7 million in Q2 2025.